Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Volume: 375, Issue: 19, Pages: 1834 - 1844
Published: Nov 10, 2016
Abstract
Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are...
Paper Details
Title
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Published Date
Nov 10, 2016
Volume
375
Issue
19
Pages
1834 - 1844
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History